RecruitingChronic Kidney Disease(CKD)Type 2 DMType 2 Diabetes Mellitus (T2DM)
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Sponsor: Duke University
You may qualify if…
- ✓ (CKD Management)
- ✓ Adults with type 2 diabetes (T2D)
- ✓ Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP)
- ✓ Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening if not checked within 3 months of enrollment):
- ✓ UACR \>300 mg/g or
- ✓ eGFR \<45 ml/min/1.73 m2 or
- ✓ UACR ≥30 mg/g with eGFR \<60 ml/min/1.73 m2
- ✓ Receiving \<100% GDMT at baseline. For patients with UACR \<30 mg/g, GDMT includes sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy. For all other eligible patients, GDMT includes ACEi/ARB, SGLT2i, and Finerenone, unless contraindications for any of these therapies exist (e.g., hyperkalemia, diabetic ketoacidosis, etc.).
You may not qualify if…
- ✕ (CKD Management)
- ✕ Type 1 diabetes
- ✕ Most recent eGFR \<20 ml/min/1.73 m2
- ✕ Prior kidney transplant
- ✕ Autosomal dominant polycystic kidney disease (ADPKD)
- ✕ Active pregnancy or plans for conception within 1 year
Where it's recruiting
Source: ClinicalTrials.gov · NCT06906640 · last updated 2026-10-01